Investigational anti-inflammatory agents for the treatment of ischaemic brain injury
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Stroke is the third leading cause of death and the leading cause of disability in Western countries. To date, only approximately 2% of stroke patients are eligible for thrombolysis treatment with recombinant tissue plasminogen activator. The very limited options available for stroke treatment and recent disappointing clinical trials in stroke call for novel therapeutic approaches. Inflammation represents one of the key pathophysiological mechanisms for the progression of ischaemic stroke. Recent advances in preclinical models of stroke using investigational small molecular antagonists, neutralising antibodies/proteins or genetically altered gene functions against various inflammatory mediators suggest a great therapeutic potential of anti-inflammation for ischaemic stroke. The scope of the present review is to update the evidence for a role of inflammatory pathways in stroke and to summarise the investigational drugs currently available both in preclinical and clinical development for potential treatment of ischaemic stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682 · cited 1×
“2 Potential anti-tumour necrosis factor therapy Three protein-based anti-TNF biologicals (etanercept, infliximab and adalimumab) have been successfully used for the treatment of rheumatoid arthritis, inflammatory bowel disease and psoriasis [98-100].”
BackgroundTumor Necrosis Factor-α: A Mediator of Focal Ischemic Brain Injury
Barone, F. C., Arvin, B., White, R. F., Miller, A., Webb, C. L., Willette, R. N., Lysko, P. G., & Feuerstein, G. Z. (1997) · Stroke · doi:10.1161/01.str.28.6.1233 · Cited by 863
A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
Borsello, T., Clarke, P. G. H., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., & Bonny, C. (2003) · Nature Medicine · doi:10.1038/nm911 · Cited by 658
Matsuo, Y., Onodera, H., Shiga, Y., Nakamura, M., Ninomiya, M., Kihara, T., & Kogure, K. (1994) · Stroke · doi:10.1161/01.str.25.7.1469 · Cited by 485 · cited 2×
“To explore a role of leukocytes in ischaemic brain tissue, antileukocyte strategies were applied by using a RP-3 mAb that selectively depletes leukocytes in the rat (∼ 90 – 95%) [68].”
BackgroundMethodMice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury
Soriano, S. G., Amaravadi, L. S., Wang, Y. F., Zhou, H., Yu, G. X., Tonra, J. R., Fairchild-Huntress, V., Fang, Q., Dunmore, J. H., Huszar, D., et al. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00033-4 · Cited by 222 · cited 1×
“Fractalkine Knockout Significant reduction in infarct size (28%) and lower mortality rate following transient MCAO [34]”
BackgroundTherapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke
Martin-Villalba, A., Hahne, M., Kleber, S., Vogel, J., Falk, W., Schenkel, J., & Krammer, P. H. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400882 · Cited by 209 · cited 3×
“For example, whereas TNF-α deficiency resulted in significant neuroprotection against transient ischaemic brain injury [33], mice deficient in TNF-R1 had a more extensive injury and TNF-R2 had no effect compared with wild-type animals after transient MCAO [32].”
BackgroundChopp, M., Li, Y., Jiang, N., Zhang, R. L., & Prostak, J. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199607000-00007 · Cited by 185 · cited 1×
“Blocking adhesion molecules can also reduce apoptosis induced by focal ischaemia [121].”
BackgroundAn Overview of Acute Stroke Therapy: Past, Present, and Future
Fisher, M., & Schaebitz, W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3196 · Cited by 112
Cited by
Inflammatory mechanisms in ischemic stroke: role of inflammatory cells
Jin, R., Yang, G., & Li, G. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1109766 · Cited by 1,521
Role of Inflammation and Its Mediators in Acute Ischemic Stroke
Jin, R., Liu, L., Zhang, S., Nanda, A., & Li, G. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9508-6 · Cited by 418
Ishrat, T., Sayeed, I., Atif, F., Hua, F., & Stein, D. G. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.08.023 · Cited by 159
“In contrast, inhibition of the inflammatory response decreases infarct size, and reduces neurological deficits after experimental stroke (Wang, 2005, Yilmaz and Granger, 2008).”
BackgroundQi, Z., Zhao, Y., Su, Y., Cao, B., Yang, J.-J., & Xing, Q. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.685088 · Cited by 44
“Accumulating evidence suggested that inflammation and immune responses play critical roles in the early stage of AIS and have been associated with the outcome of AIS (Wang, 2005; Chamorro and Hallenbeck, 2006).”
Background
Metadata
- Authors
- Wang, X.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2005-04
- Volume
- 14
- Issue
- 4
- Pages
- 393-409
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2035336513
- Cited by
- 57
- References
- 8
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.